NYSE · WHOLESALE-DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES · MID CAP
NU Skin Enterprises, Inc. NUS
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY5 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
$1.5B
▼ 14.3% vs FY2024
Dividend streak
5 yrs
Raised every year since 2021
EPS · FY25
$3.18
Dividend / sh · FY25
—
Payout · FY25
7%
ROE · FY25
22.0%
Net margin · FY25
10.8%
Dividend coverage
6.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.5B
Revenue, FY2025 · full 18-year series below
Revenue
Net income
11 cents of every revenue dollar became profit this year.
Per share
USD 3.18
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 6.4 times — the rest stayed in the company.
Profitability
22.0%
Return on equity, FY2025
ROE
Operating margin4.4%
Net margin10.8%
Return on assets11.1%
Each USD of equity produced 22 cents of profit this year.
Returned to shareholders
USD 31.9M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 11.8M
Net buybacksUSD 20.0M
Share of profit19.9%
Consecutive raises5 years
USD 11.8M in dividends and USD 20.0M in buybacks — 20% of the year's profit went back to shareholders.
Growth
−10.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−12.6%
−10.5%
−4.1%
−0.2%
Net income
+15.2%
−3.5%
+1.9%
+1.1%
EPS, diluted
+15.4%
−2.6%
+3.5%
+2.8%
Dividend / share
+20.5%
+22.9%
Returned to shareholders
−39.9%
−32.2%
−18.5%
−5.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD 805.2M
CashUSD 238.6M
Gross debtUSD 224.2M
Net debtUSD -14.4M
Current ratio2.08×
The company holds more cash than debt.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
1.5
1.7
2.0
2.2
2.7
2.6
2.4
2.7
2.3
2.2
2.2
2.6
3.2
2.1
1.7
1.5
1.3
·
Operating income $B
0.1
−0.2
0.0
0.1
0.2
0.3
0.3
0.2
0.3
0.2
0.2
0.4
0.6
0.3
0.2
0.2
0.1
0.1
EBITDA $B
0.1
−0.1
0.1
0.2
0.3
0.3
0.3
0.3
0.3
0.3
0.3
0.4
0.6
0.4
0.3
0.2
0.2
0.2
Income tax $B
0.0
−0.0
0.0
−0.0
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.2
0.1
0.1
0.1
0.1
0.0
Net income $B
0.2
−0.1
0.0
0.1
0.1
0.2
0.2
0.1
0.1
0.1
0.1
0.2
0.4
0.2
0.2
0.1
0.1
0.1
EPS, diluted $
3.18
−2.95
0.17
2.07
2.86
3.63
3.10
2.16
2.36
2.55
2.25
3.11
5.94
3.52
2.38
2.11
1.40
1.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
0.35
0.34
0.30
0.20
0.16
0.12
·
·
Payout %
7
−8
903
74
52
41
47
66
59
55
61
43
19
22
24
23
32
43
ROE %
22.0
−19.9
1.0
11.6
16.3
21.6
20.9
16.4
18.9
19.2
15.0
21.0
50.4
38.1
29.3
32.1
26.0
20.7
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
69 of 69
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed